Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation
Transplantation Proceedings · 2026-07 · 58 (6) · 1092-1096
DOI: 10.1016/j.transproceed.2026.05.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2026-07. Verfasst von Anju Pradeep und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan. Electronic address: apradee1@hfhs.org. Hauptthemen laut MEDLINE: Liver Transplantation, Glucagon-Like Peptide 1, Body Weight. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION Glucagon-Like Peptide-1 (GLP-1) analogues are increasingly being used to manage diabetes and obesity. However, their use in liver transplant (LT) recipients remains understudied. This study aimed to evaluate the clinical outcomes associated with GLP-1 use following LT. METHODS We conducted a retrospective cohort study of adult LT recipients between 2019-2023 at a single tertiary care center. Patients were divided into 2 groups based on GLP-1 use after transplant. Baseline demographics, comorbidities, transplant characteristics, and post-transplant outcomes were compared. Categorical variables were analyzed using Chi-square tests, and continuous variables using t-tests. RESULTS Among 368 LT recipients, 73 (19.8%) were prescribed GLP-1 analogues post-transplant and 295 (80.2%) were not. There was no difference in demographics. GLP-1 users had higher rates of diabetes (79.5% vs. 31.2%, p < .0001), hyperlipidemia (50.7% vs. 29.8%, p = .0012), and BMI at transplant (31.9 ± 6.3 vs. 28.5 ± 12.6, p = .0015). MASH was the leading indication for transplant in the GLP-1 group (61.9% vs. 38.1%, p < .0001). At year 1, GLP-1 users had lower rejection rates (12.3% vs. 23.1%, p = .0635), with a similar trend at 3 years (6.8% vs. 9.5%, p = .6322). At 3 years, mortality was lower in GLP-1 users (1.4% vs. 4.7%, p = .3293). DISCUSSION GLP-1 analogues were commonly used post-LT in patients with MASH and obesity. Despite higher metabolic burden at baseline, GLP-1 use was associated with similar or improved trends in BMI, rejection, and mortality. Larger prospective studies are needed to strengthen the evidence supporting the use of GLP-1 analogues in this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan. Electronic address: apradee1@hfhs.org.
- Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan.
- Wayne State University, Detroit, Michigan.
- Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania.
- King Edward Medical University, Lahore, Pakistan.
- Department of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, Michigan.
Zitieren
APA
Pradeep, A., Faisal, M. S., Chen, K., Gokturk, T., Karmo, B., Rosario, A. G., Rocha, I., Shahzil, M., Fatima, M., Rehmani, M., Obri, M., Faisal, M. S., & Jafri, S. M. (2026). Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation. Transplantation Proceedings, 58(6), 1092-1096. https://doi.org/10.1016/j.transproceed.2026.05.018
Vancouver
Pradeep A, Faisal MS, Chen K, Gokturk T, Karmo B, Rosario AG, et al. Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation. Transplantation Proceedings. 2026;58(6):1092-1096. doi:10.1016/j.transproceed.2026.05.018
BibTeX
@article{Pradeep2026,
author = {Pradeep, Anju and Faisal, Muhammad Saad and Chen, Kelly and Gokturk, Tepe and Karmo, Bradley and Rosario, Agustin Gavidia and Rocha, Ingrid and Shahzil, Muhammad and Fatima, Minahil and Rehmani, Maria and Obri, Mark and Faisal, Muhammad Salman and Jafri, Syed-Mohammed},
title = {Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation},
journal = {Transplantation Proceedings},
year = {2026},
volume = {58},
number = {6},
pages = {1092--1096},
doi = {10.1016/j.transproceed.2026.05.018}
}
EUVIMED